The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Open accessAbstract
BACKGROUND: New therapies are needed to manage the increasing incidence, severity, and high rate of recurrence of Clostridium difficile infection. METHODS: We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins A (CDA1) and B (CDB1). The antibodies were administered together as a single infusion, each at a dose of 10 mg per kilogram of body weight, in patients with symptomatic C. difficile infection who were receiving either metronidazole or vancomycin. The primary outcome was laboratory-documented recurrence of infection during the 84 days after the administration of monoclonal antibodies or placebo. RESULTS: Among the 200 patients who were enrolled (101 in the antibody group and 99 in the placebo group), the rate of recurrence of C. difficile infection was lower among patients treated with monoclonal antibodies (7% vs. 25%; 95% confidence interval, 7 to 29; P<0.001). The recurrence rates among patients with the epidemic BI/NAP1/027 strain were 8% for the antibody group and 32% for the placebo group (P=0.06); among patients with more than one previous episode of C. difficile infection, recurrence rates were 7% and 38%, respectively (P=0.006). The mean duration of the initial hospitalization for inpatients did not differ significantly between the antibody and placebo groups (9.5 and 9.4 days, respectively). At least one serious adverse event was reported by 18 patients in the antibody group and by 28 patients in the placebo group (P=0.09). CONCLUSIONS: The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection. (ClinicalTrials.gov number, NCT00350298.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
Asymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420604 · Cited by 935
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804
Toxin B is essential for virulence of Clostridium difficile
Lyras, D., O’Connor, J. R., Howarth, P. M., Sambol, S. P., Carter, G. P., Phumoonna, T., Poon, R., Adams, V., Vedantam, G., Johnson, S., et al. (2009) · Nature · doi:10.1038/nature07822 · Cited by 745
Self-citationGoorhuis, A., Bakker, D., Corver, J., Debast, S. B., Harmanus, C., Notermans, D. W., Bergwerff, A. A., Dekker, F. W., & Kuijper, E. J. (2008) · Clinical Infectious Diseases · doi:10.1086/592257 · Cited by 637
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Human Botulism Immune Globulin for the Treatment of Infant Botulism
Arnon, S. S., Schechter, R., Maslanka, S. E., Jewell, N. P., & Hatheway, C. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051926 · Cited by 498
Killgore, G., Thompson, A., Johnson, S., Brazier, J., Kuijper, E., Pepin, J., Frost, E. H., Savelkoul, P., Nicholson, B., van den Berg, R. J., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01484-07 · Cited by 337
Self-citationFour Country Healthcare Associated Infection Prevalence Survey 2006: overview of the results
Smyth, E. T. M., McIlvenny, G., Enstone, J. E., Emmerson, A. M., Humphreys, H., Fitzpatrick, F., Davies, E., Newcombe, R. G., & Spencer, R. C. (2008) · Journal of Hospital Infection · doi:10.1016/j.jhin.2008.04.020 · Cited by 310
Leung, D. Y. M., Kelly, C. P., Boguniewicz, M., Pothoulakis, C., LaMont, J. T., & Flores, A. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83393-1 · Cited by 278
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis
Salcedo, J., Keates, S., Pothoulakis, C., Warny, M., Castagliuolo, I., LaMont, J. T., & Kelly, C. P. (1997) · Gut · doi:10.1136/gut.41.3.366 · Cited by 264
Babcock, G. J., Broering, T. J., Hernandez, H. J., Mandell, R. B., Donahue, K., Boatright, N., Stack, A. M., Lowy, I., Graziano, R., Molrine, D., et al. (2006) · Infection and Immunity · doi:10.1128/iai.00982-06 · Cited by 257
Self-citationPepin, J., Routhier, S., Gagnon, S., & Brazeau, I. (2006) · Clinical Infectious Diseases · doi:10.1086/501126 · Cited by 246
Gravel, D., Miller, M., Simor, A., Taylor, G., Gardam, M., McGeer, A., Hutchinson, J., Moore, D., Kelly, S., Boyd, D., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596703 · Cited by 243
Hu, M. Y., Katchar, K., Kyne, L., Maroo, S., Tummala, S., Dreisbach, V., Xu, H., Leffler, D. A., & Kelly, C. P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.038 · Cited by 242
Clabots, C. R., Johnson, S., Bettin, K. M., Mathie, P. A., Mulligan, M. E., Schaberg, D. R., Peterson, L. R., & Gerding, D. N. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.7.1870-1875.1993 · Cited by 170
Self-citationThe Challenges Posed by Reemerging Clostridium difficile Infection
Blossom, D. B., & McDonald, L. C. (2007) · Clinical Infectious Diseases · doi:10.1086/518874 · Cited by 169
Recurrent Clostridium Difficile
Maroo, S., & Lamont, J. T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.044 · Cited by 163
Kink, J. A., & Williams, J. A. (1998) · Infection and Immunity · doi:10.1128/iai.66.5.2018-2025.1998 · Cited by 159
Update on the changing epidemiology of Clostridium difficile-associated disease
McFarland, L. V. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1029 · Cited by 149
Kim, P. H., Iaconis, J. P., & Rolfe, R. D. (1987) · Infection and Immunity · doi:10.1128/iai.55.12.2984-2992.1987 · Cited by 136
Santosham, M., Reid, R., Ambrosino, D. M., Wolff, M., Almeido-Hill, J., Priehs, C., Aspery, K. M., Garrett, S., Croll, L., Foster, S. L., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171503 · Cited by 133
Self-citationGiannasca, P. J., Zhang, Z., Lei, W.-D., Boden, J. A., Giel, M. A., Monath, T. P. C., & Thomas, W. D. (1999) · Infection and Immunity · doi:10.1128/iai.67.2.527-538.1999 · Cited by 113
Self-citationEssential Involvement of IFN-γ in Clostridium difficile Toxin A-Induced Enteritis
Ishida, Y., Maegawa, T., Kondo, T., Kimura, A., Iwakura, Y., Nakamura, S., & Mukaida, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3018 · Cited by 111
Serum IgG mediates mucosal immunity against rotavirus infection
Westerman, L. E., McClure, H. M., Jiang, B., Almond, J. W., & Glass, R. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502437102 · Cited by 82
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Emerging infectious diseases · doi:10.3201/eid1411.080337 · Cited by 71
Taylor, C. P., Tummala, S., Molrine, D. C., Davidson, L. E., Farrell, R. J., Lembo, A. J., Hibberd, P. L., Lowy, I., & Kelly, C. P. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.042 · Cited by 54
Self-citationClostridium difficile— Beyond Antibiotics
Kyne, L. (2010) · New England Journal of Medicine · doi:10.1056/nejme0910055 · Cited by 48
Active and passive immunization to protect against antibiotic associated caecitis in hamsters.
Fernie, D. S., Thomson, R. O., Batty, I., & Pd, W. (1983) · PubMed · Cited by 44
Sutton, P. A., Li, S., Webb, J., et al. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03690.x · Cited by 24
Reining in Recurrent Clostridium difficile Infection—Who's at Risk?
Surawicz, C. M. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.023 · Cited by 19
The Second International Conference on Women and Infectious Diseases
McDonald, M., & Romero‐Steiner, S. (2006) · Emerging infectious diseases · doi:10.3201/eid1211.061025 · Cited by 12
Cited by
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationGuidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Microbiota-mediated colonization resistance against intestinal pathogens
Buffie, C. G., & Pamer, E. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3535 · Cited by 1,564
Clostridium difficile Infection
Leffler, D. A., & Lamont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,450
Metadata
- Authors
- Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Leney, M., Sloan, S., Hay, C. A., & Ambrosino, D. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-01-21
- Volume
- 362
- Issue
- 3
- Pages
- 197-205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2144370711
- Cited by
- 746
- References
- 34
- FWCI
- 57.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.